IMATINIB ACCORD 100 mg, film-coated tablet 60 tablets, CIP 3400930266731
Active ingredients: Imatinib, Imatinib mesylate
Commercialized according to BDPMDispensing in France: Prescription only
Film-coated tablet60 tablets, CIP 3400930266731orale
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- IMATINIB ACCORD 100 mg, comprimé pelliculé
- Pharmaceutical form
- comprimé pelliculé
- Route of administration
- orale
- Presentation description
- 60 plaquette(s) thermoformée(s) aluminium de 1 comprimé(s)
- Marketing authorisation holder
- ACCORD HEALTHCARE (ESPAGNE)
- Reimbursement according to BDPM
- 100 %
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 5 Feb 2024
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Initial prescription by a hospital doctor
- Initial prescription by a specialist
- Renewal by a specialist only
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
65896314CIP73026673CIP133400930266731Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| IMATINIBcomprimé | 100 mg · un comprimé | FT |
| MÉSILATE D'IMATINIBcomprimé | 119,500 mg · un comprimé | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Other packages of this medicine
The same medicine in another pack size, according to BDPM.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.